Abstract
Aim We have previously reported that more than half of HLA-sensitized renal transplant candidates also exhibit anti-angiotensin II type 1 receptor antibody (AT1R-Ab). AT1R-Ab has been associated with antibody-mediated rejection and worse allograft survival. The aim of the present study was to prospectively compare the natural evolution of AT1R-Ab levels with response to desensitization therapy. Methods Ninety-three patients receiving desensitization therapy (VDS group, N = 23) or without desensitization therapy (non-VDS group, N = 70) had AT1R-Ab levels determined ELISA (U/mL after 1:50 dilution), before and after desensitization (VDS group) or before and after transplantation (non-VDS group). Results Initial AT1R-Ab levels were higher in VDS (17.64 ± 10.62 U/mL) then in non-VDS group (13.01 ± 9.14 U/mL, p Conclusions More than half of HLA-sensitized candidates exhibit AT1R-Ab. This initial desensitization experience consistently provided substantial reductions of AT1R-Ab levels in an unselected, highly sensitized kidney transplant candidate population, reduction that is more pronounced that post-transplant natural antibody dynamics. Download : Download high-res image (104KB) Download : Download full-size image
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call